Type A meeting with U.S. FDA scheduled to discuss Deramiocel BLA and path toward potential approvalCapricor seeks to resubmit ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Capricor Therapeutics Inc. (CAPR) on Monday reported a loss of $25.9 million in its second quarter. On a per-share basis, the San Diego-based company said it had a ...

Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration ...

Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.

Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.

Company to Host Conference Call on August 13, 2025, at 4:30 p.m. ET –SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Capricor ...

Capricor Therapeutics Inc.‘s board overhyped regulatory approval odds for its cell therapy to treat a serious heart condition, leading to a series of stock drops, a shareholder lawsuit said.

The shares of biotech companies fell after news that ousted regulator Vinay Prasad is set to go back to the US Food and Drug Administration.Prasad had previously overruled his own scientific review ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: ...

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases.

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases.

Capricor Therapeutics Inc. CAPR is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock surged ...